Cargando…
Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
In the 70 years following the first description of the benefits of surgical castration, despite advances in medical therapy e.g. cabazitaxel, enzalutamide, abiraterone, androgen deprivation therapy (ADT) remains the cornerstone of treatment for advanced prostate cancer. However, with increasing numb...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553523/ https://www.ncbi.nlm.nih.gov/pubmed/23321508 http://dx.doi.org/10.1038/bjc.2012.523 |